Dr. Majerus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-362-7216Fax+1 314-362-8813
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2000 - 2003
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2000
- Saint Louis University School of MedicineClass of 1998
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 1999 - 2026
Clinical Trials
- A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
Publications & Presentations
PubMed
- Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.Andrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington, Doris V Quon
Research and Practice in Thrombosis and Haemostasis. 2024-11-01 - 2 citationsPegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity.Koo Wilson, Carly Rich, Zalmai Hakimi, Regina Horneff, Jesse Fishman
European Journal of Haematology. 2024-04-01 - 3 citationsHealth-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.Brian O'Mahony, Amy L Dunn, Andrew D Leavitt, Flora Peyvandi, Margareth C Ozelo
Journal of Thrombosis and Haemostasis. 2023-12-01
Press Mentions
- Dr. Philip Majerus, Among the First to Discern Aspirin’s Heart Benefits, Dies at 79June 14th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: